JUPW News and Press, Jupiter Wellness Inc. From 05/04/22

JW-300 Demonstrated Efficacy in the Treatment of Developing Burns (sunburn) in a Double-Blinded Placebo-Controlled Clinical Trial JUPITER, FL / ACCESSWIRE / May 4, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW) will present data for Jupiter's JW-300, a cannabidiol topical treatment f...

Jupiter Wellness (NASDAQ:JUPW) concluded an Asset Purchase Agreement with Ascent Clinical Research through which it has acquired certain clinical assets including clinical trial research contracts worth $3M in annual revenues for a purchase price of 5% royalties on future net revenues ge...

IN A BID TO EXPAND JUPITER WELLNESS'S RESEARCH CAPABILITIES AND ENTER THE LUCRATIVE CRO BUSINESS, JUPITER WELLNESS ACQUIRED THE ASSETS OF ASCENT CLINICAL RESEARCH JUPITER, FL / ACCESSWIRE / April 27, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW) today announced it has concluded an Ass...

JUPITER, FL / ACCESSWIRE / April 18, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW) today announced that it has appointed three sales and marketing executives to its team to drive sales of its science-backed proprietary brands and products. Over the past two years, Jupiter has built a port...

Exclusive Worldwide Rights to Patented Shark Repellent Technologies for the Sun and Skin Market Licensed From Shark Defense Technologies, the Leader in Its Field Featured in Numerous Media Outlets Including Discovery Channel's Shark Week and Animal Planet View Discovery Channel Videos o...

Authored by an International Group of Leading Dermatology Researchers and Clinicians Who Conducted the Studies JUPITER, FL / ACCESSWIRE / April 6, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW) , today announced the publication of clinical study results to investigate the safety and e...

Jupiter licenses exclusive worldwide rights for unique formulas addressing jellyfish and man o' war stings, sea lice, and swimmer's itch with 4 patents-pending Estimated 150 million people are stung by jellyfish globally each year JUPITER, FL / ACCESSWIRE / April 5, 2022 / Jupit...

Data expected Q1 2022 on efficacy of JW-200 to clear AK lesions, a common form of pre-cancerous growth that left untreated can lead to cancer in up to 15% of patients JUPITER, FL / ACCESSWIRE / February 18, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW) today announced it has completed...

JUPITER, FL / ACCESSWIRE / February 15, 2022 / Jupiter Wellness , Inc. (Nasdaq:JUPW) today announced that its merger partner Next Frontier Pharmaceuticals' Executive Chairman Shannon Soqui was interviewed on Benzinga's All Access 6 Emerging Growth Companies To Watch In 2022 program wh...

Corporate Presentation Highlights Merged Company's Strength as Leading Drug Developer Focused on Pharma Cannabinoids: LINK JUPITER, FL / ACCESSWIRE / February 2, 2022 / Jupiter Wellness , Inc. (NASDAQ:JUPW ) today announced that its CEO Brian John and Next Frontier Pharmaceutica...